Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04013672
Title Phase II Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Manmeet Ahluwalia, MD
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.